The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim

References

1. 1.↵
   International Conference for Harmonisation, ICH Harmonized Tripartite Guideline: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin Q5A (R1), Step 4 Version, ICH Geneva, 1999.
2. 2.↵
   1. Miesegaes G.,
   2. Lute S.,
   3. Brorson K.

   Analysis of Viral Clearance Unit Operations for Monoclonal Antibodies. Biotechnol. Bioeng. 2010, 106 (2), 238–246.

   OpenUrlPubMed
3. 3.↵
   1. Miesegaes G.,
   2. Bailey M.,
   3. Willkommen H.,
   4. Chen Q.,
   5. Roush D.,
   6. Blümel J.,
   7. Brorson K.

   Proceedings of the 2009 Viral Clearance Symposium. Dev. Biol. (Basel, Switz.) 2010, 133, 3–101.

   OpenUrl
4. 4.↵
   1. Edwards J.,
   2. Mann E.,
   3. Brown D. T.

   Conformational Changes in Sindbis Virus Envelope Proteins Accompanying Exposure to Low pH. J. Virol. 1983, 45 (3), 1090–1097.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Brorson K.,
   2. Krejci S.,
   3. Lee K.,
   4. Hamilton E.,
   5. Stein K.,
   6. Xu Y.

   Bracketed Generic Inactivation of Rodent Retroviruses by Low pH Treatment for Monoclonal Antibodies and Recombinant Proteins. Biotechnol. Bioeng. 2003, 82 (3), 321–329.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Vacante D.,
   2. Connell-Crowley L.

   Protocol for Evaluation of Virus Inactivation Using Low-pH Treatment. PDA J. Pharm. Sci. Technol. 2014, 68 (1), 90–97.

   OpenUrlFREE Full Text
7. 7.↵
   1. Mattila J.,
   2. Clark M.,
   3. Liu S.,
   4. Pieracci J.,
   5. Gervais T. R.,
   6. Wilson E.,
   7. Galperina O.,
   8. Li X.,
   9. Roush D.,
   10. Zoeller K.,
   11. Brough H.,
   12. Simpson-Platre C.

   Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration. PDA J. Pharm. Sci. Technol. 2016, 70 (3), 293–299.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Chinniah S.,
   2. Hinckley P.,
   3. Connell-Crowley L.

   Characterization of Operating Parameters for MuLV Inactivation by Low pH Treatment. Biotechnol. Prog. 2016, 32 (1), 89–97.

   OpenUrl
9. 9.↵
   U.S. Food and Drug Administration. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 1997.
10. 10.↵
    1. Strauss D. M.,
    2. Cano T.,
    3. Cai N.,
    4. Delucchi H.,
    5. Plancarte M.,
    6. Coleman D.,
    7. Blank G. S.,
    8. Chen Q.,
    9. Yang B.

    Strategies for Developing Design Spaces for Viral Clearance by Anion Exchange Chromatography during Monoclonal Antibody Production. Biotechnol. Prog. 2010, 26 (3), 750–755.

    OpenUrlPubMed
11. 11.↵
    1. Stuckey J.,
    2. Strauss D.,
    3. Venkiteshwaran A.,
    4. Gao J.,
    5. Luo W.,
    6. Quertinmont M.,
    7. O'Donnell S.,
    8. Chen D.

    A Novel Approach to Achieving Modular Retrovirus Clearance for a Parvovirus Filter. Biotechnol. Prog. 2014, 30 (1), 79–85.

    OpenUrlCrossRef
12. 12.↵
    ASTM Standard E 2888: Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. In ASTM Volume 14.05 Statistical Methods; Hazard Potential of Chemicals; Thermal Measurements; Manufacture of Pharmaceutical and Biopharmaceutical Products [Online]; ASTM International: West Conshohocken, PA, 2012.
13. 13.↵
    1. Iskra T.,
    2. Sacramo A.,
    3. Gallo C.,
    4. Godavarti R.,
    5. Chen S.,
    6. Lute S.,
    7. Brorson K.

    Development of a Modular Virus Clearance Package for Anion Exchange Chromatography Operated in Weak Partitioning Mode. Biotechnol. Prog. 2015, 31 (3), 750–757.

    OpenUrl
14. 14.↵
    1. Durno L.,
    2. Tounekti O.

    Viral Inactivation: Low pH and Detergent. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 163–172.

    OpenUrlFREE Full Text